Peripheral Arterial Disease

• 

  Subject Areas on Research

  • 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. 
  • 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. 
  • A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia. 
  • ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). 
  • ADAM12: a genetic modifier of preclinical peripheral arterial disease. 
  • Accelerated epigenetic age as a biomarker of cardiovascular sensitivity to traffic-related air pollution. 
  • Acute Limb Ischemia in Peripheral Artery Disease. 
  • Acute Limb Ischemia. 
  • Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. 
  • An endovascular model of ischemic myopathy from peripheral arterial disease. 
  • An evidence-based score to detect prevalent peripheral artery disease (PAD). 
  • Analysis of 30-day readmission after aortoiliac and infrainguinal revascularization using the American College of Surgeons National Surgical Quality Improvement Program data set. 
  • Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. 
  • Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. 
  • Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. 
  • Ankle-brachial index and cardiovascular risk prediction: an analysis of 11,594 individuals with 10-year follow-up. 
  • Ankle-brachial index as a predictor of coronary disease events in elderly patients submitted to coronary angiography. 
  • Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered and clinician-based evaluations of functional status. 
  • Antithrombotic Therapy After Peripheral Vascular Intervention. 
  • Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. 
  • Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. 
  • Apheresis to Mitigate Atherosclerotic Vascular Disease. 
  • Arterial reconstruction with human bioengineered acellular blood vessels in patients with peripheral arterial disease. 
  • Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. 
  • Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial. 
  • Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. 
  • Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. 
  • Associations Between Residential Proximity to Traffic and Vascular Disease in a Cardiac Catheterization Cohort. 
  • Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. 
  • Balloon-assisted tracking: a must-know technique to overcome difficult anatomy during transradial approach. 
  • Beet the Best? 
  • CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. 
  • Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. 
  • Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. 
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
  • Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. 
  • Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Centers for Medicare & Medicaid Services' decision on drug-coated balloons: No additional reimbursement despite higher cost and highest levels of scientific evidence. 
  • Challenges in Peripheral Artery Disease Clinical Trial Implementation and Design. 
  • Characteristics and Outcomes of Patients With Diabetes Mellitus Undergoing Peripheral Vascular Intervention for Infrainguinal Symptomatic Peripheral Artery Disease. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. 
  • Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. 
  • Cigarette Smoking and Subclinical Peripheral Arterial Disease in Blacks of the Jackson Heart Study. 
  • Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. 
  • Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. 
  • Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. 
  • Clinician Specialty, Access to Care, and Outcomes Among Patients with Peripheral Artery Disease. 
  • Co-existence of vascular disease in different arterial beds: Peripheral artery disease and carotid artery stenosis--Data from Life Line Screening(®). 
  • Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. 
  • Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia: systematic review of revascularization in critical limb ischemia. 
  • Comparative effectiveness review of antiplatelet agents in peripheral artery disease. 
  • Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. 
  • Crossing Peripheral Chronic Total Occlusions: More Tolls and More Questions. 
  • Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. 
  • Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. 
  • Diabetes status differentiates endothelial function and plasma nitrite response to exercise stress in peripheral arterial disease following supervised training. 
  • Diagnosis and treatment of peripheral arterial disease. 
  • Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. 
  • Distribution of ankle--brachial index and the risk factors of peripheral artery disease in a multi-ethnic Asian population. 
  • Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. 
  • Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. 
  • Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION). 
  • Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 
  • Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. 
  • Effects of a 12-Week mHealth Program on FunctionalCapacity and Physical Activity in Patients With PeripheralArtery Disease. 
  • Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. 
  • Endovascular therapy: is it effective in the diabetic limb? 
  • Endovascular treatment of femoro-popliteal lesions. 
  • Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire. 
  • Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. 
  • Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). 
  • Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry. 
  • Factors Associated With and Outcomes of Aborted Procedures During Elective Transcatheter Aortic Valve Replacement. 
  • Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study. 
  • Genetic Variants in the Bone Morphogenic Protein Gene Family Modify the Association between Residential Exposure to Traffic and Peripheral Arterial Disease. 
  • Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. 
  • High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. 
  • High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. 
  • High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. 
  • Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease. 
  • Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. 
  • Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. 
  • Implementing a home-based exercise prescription for older patients with peripheral arterial disease and intermittent claudication: a quality improvement project. 
  • Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program. 
  • Improving outcomes in patients with peripheral arterial disease. 
  • Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. 
  • Laser in infrapopliteal and popliteal stenosis 2 study (LIPS2): Long-term outcomes of laser-assisted balloon angioplasty versus balloon angioplasty for below knee peripheral arterial disease. 
  • Learning to walk before we run: the mechanics of medical intervention for peripheral arterial disease. 
  • Letter by Moris et al Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease". 
  • Letter by Siasos et al Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease". 
  • Limb ischemia: cardiovascular diagnosis and management from head to toe. 
  • Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. 
  • Longitudinal changes in high-density lipoprotein cholesterol and cardiovascular events in older adults. 
  • Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. 
  • Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. 
  • Lower extremity amputation in peripheral artery disease: improving patient outcomes. 
  • Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization. 
  • Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. 
  • Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. 
  • New Curveball for Hypertension Guidelines? 
  • No Increase in All-Cause Mortality at 2 Years Among Patients Undergoing Drug-Coated Balloon Angioplasty. 
  • Noncardiac surgery: widening the gap in pulse pressure. 
  • Novel CenterCross and MultiCross devices for the treatment of infrainguinal chronic total occlusions: initial single-centre experience. 
  • Outcome of lower extremity revascularization for peripheral artery occlusive disease: is there a difference between men and women? 
  • Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. 
  • Outcomes of surgical revascularization for lower extremity arterial thromboembolism in patients with advanced malignancy. 
  • PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories): Overview of Design and Rationale of an International Prospective Peripheral Arterial Disease Study. 
  • Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. 
  • Patient Radiation Dosage During Lower Extremity Endovascular Intervention. 
  • Patient-Reported Outcome Measures in Symptomatic, Non-Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review. 
  • Peripheral Artery Disease Therapies May Perform Differently in Practice Than in Randomized Trials: The Need for Learning Health Systems. 
  • Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry. 
  • Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. 
  • Peripheral arterial testing before lower extremity amputation among Medicare beneficiaries, 2000 to 2010. 
  • Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. 
  • Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. 
  • Polyvascular Disease: Reappraisal of the Current Clinical Landscape. 
  • Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. 
  • Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. 
  • Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Prevalence of hypertension and peripheral arterial disease in adults in Léogâne, Haiti 
  • Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. 
  • Radial Access for Peripheral Interventions. 
  • Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). 
  • Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. 
  • Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements. 
  • Registry Assessment of Peripheral Interventional Devices (RAPID)　- Registry Assessment of Peripheral Interventional Devices Core Data Elements. 
  • Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions. 
  • Reinterventions in the superficial femoral artery. 
  • Relation between sex hormone concentrations, peripheral arterial disease, and change in ankle-brachial index: findings from the Framingham Heart Study. 
  • Relation of Baseline Renal Dysfunction With Outcomes in Patients Undergoing Popliteal and Infrapopliteal Percutaneous Peripheral Arterial Interventions. 
  • Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. 
  • Relationship of systemic endothelial function and peripheral arterial stiffness with diabetic retinopathy. 
  • Reply: Era of Change in Sites of Service for Peripheral Vascular Intervention Requires New Ways to Look at Costs. 
  • Response by Jones et al to Letter Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease". 
  • Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization". 
  • Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization. 
  • Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. 
  • Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. 
  • Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. 
  • Rivaroxaban in Peripheral Artery Disease after Revascularization. 
  • Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial. 
  • Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. 
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. 
  • Safety and Effectiveness of Retrograde Arterial Access for Endovascular Treatment of Critical Limb Ischemia. 
  • Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. 
  • Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. 
  • Skeletal muscle capillary density is related to anaerobic threshold and claudication in peripheral artery disease. 
  • Socioeconomic disparities in the use of cardioprotective medications among patients with peripheral artery disease: an analysis of the American College of Cardiology's NCDR PINNACLE Registry. 
  • Spliced arm vein grafts are a durable conduit for lower extremity bypass. 
  • Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. 
  • Statin therapy--Part II: Clinical considerations for cardiovascular disease. 
  • Stroke in Patients With Peripheral Artery Disease. 
  • Successful Peripheral Vascular Intervention in Patients with High-risk Comorbidities or Lesion Characteristics. 
  • Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration. 
  • Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. 
  • Systemic hypersensitivity reaction to endovascular stainless steel stent. 
  • Temporal trends and geographic variation of lower-extremity amputation in patients with peripheral artery disease: results from U.S. Medicare 2000-2008. 
  • The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease. 
  • The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target? 
  • The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. 
  • The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. 
  • The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease. 
  • The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. 
  • The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). 
  • The impact of chronic kidney disease on outcomes following peripheral vascular intervention. 
  • Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. 
  • Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. 
  • Ticagrelor versus Clopidogrel in Peripheral Artery Disease. 
  • Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. 
  • Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. 
  • Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. 
  • Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. 
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. 
  • Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. 
  • Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease. 
  • Use of Natural Language Processing to Improve Identification of Patients With Peripheral Artery Disease. 
  • Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. 
  • Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. 
  • Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). 
  • Vorapaxar in the secondary prevention of atherothrombotic events. 
  • World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. 
• 

  Keywords of People

  • Jones, William Schuyler, Associate Professor of Medicine, Medicine, Cardiology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology